Dirk Theile

ORCID

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 16

Top Venues

Archives of toxicology

British journal of clinical pharmacology

Naunyn-Schmiedeberg's archives of pharmacology

International journal of cancer

University Hospital Heidelberg

University Hospital Heidelberg (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

University Hospital Heidelberg Oct 01 2006

Germany

Scientist :: Clinical Pharmacology & Pharmacoepidemiology

Beckman Research Institute, City of Hope Jan 15 2015 - Jul 05 2016

United States

Postdoctoral Fellow :: Cancer Biology

Education History

University Hospital Heidelberg Oct 01 2006 - Nov 07 2010

Germany

PHD :: Clinical Pharmacology & Pharmacoepidemiology

University of Heidelberg Oct 01 2003 - Sep 01 2005

Germany

MSC

Karlsruhe Institute of Technology Oct 01 2001 - Jul 01 2003

Germany

BSC

Publications

Dirk Theile, David Czock
Perfusate Flow Rate: An Overlooked Factor in Hyperthermic Intraperitoneal Chemotherapy (HIPEC)? Annals of surgical oncology (2024)
Julie Nilles, Johanna Weiss, Max Sauter, Walter E Haefeli, Stephanie Ruez, Dirk Theile
Comprehensive in vitro analysis evaluating the variable drug-drug interaction risk of rifampicin compared to rifabutin. Archives of toxicology (2023)
Lottida Phondeth, Rajamanikkam Kamaraj, Julie Nilles, Johanna Weiss, Walter E Haefeli, Petr Pávek, Dirk Theile
Rifabutin but not rifampicin can partly out-balance P-glycoprotein induction by concurrent P-glycoprotein inhibition through high affinity binding to the inhibitory site. Archives of toxicology (2023)
Dirk Theile, Julie Nilles, Andreas Daniel Meid
Physiology-based pharmacokinetic modelling and experimental data suggest that rifabutin alters dolutegravir kinetics by both P-glycoprotein induction and concurrent inhibition. British journal of clinical pharmacology (2023)
Julie Nilles, Johanna Weiss, Dirk Theile
Crystal violet staining is a reliable alternative to bicinchoninic acid assay-based normalization. BioTechniques 73 (3) (2022)
Rémi Longuespée, Dirk Theile, Inka Zörnig, Jessica C Hassel, Joshua Raoul Lindner, Walter E Haefeli, Margaux Fresnais
Molecular prediction of clinical response to anti-PD-1/anti-PD-L1 immune checkpoint inhibitors: New perspectives for precision medicine and mass spectrometry-based investigations. International journal of cancer (2022)
Julie Nilles, Johanna Weiss, Walter E Haefeli, Stephanie Ruez, Dirk Theile
How to avoid misinterpretation of dual reporter gene assay data affected by cell damage. Archives of toxicology 96 (9) (2022)
Juan Pablo Rigalli, Dirk Theile, Julie Nilles, Johanna Weiss
Regulation of PXR Function by Coactivator and Corepressor Proteins: Ligand Binding Is Just the Beginning. Cells 10 (11) (2021)
Dirk Theile, Pauline Wizgall
Acquired ABC-transporter overexpression in cancer cells: transcriptional induction or Darwinian selection? Naunyn-Schmiedeberg's archives of pharmacology 394 (8) (2021)
Margaux Fresnais, Sevin Turcan, Dirk Theile, Johannes Ungermann, Yasmin Abou Zeed, Joshua Raoul Lindner, Marius Breitkopf, Juergen Burhenne, Walter Emil Haefeli, Rémi Longuespée
Approaching Sites of Action of Temozolomide for Pharmacological and Clinical Studies in Glioblastoma. Biomedicines 10 (1) (2021)
Dirk Theile, Lelia Wagner, Cindy Bay, Walter Emil Haefeli, Johanna Weiss
Time-Resolved Effect of Interferon-Alpha 2a on Activities of Nuclear Factor Kappa B, Pregnane X Receptor and on Drug Disposition Genes. Pharmaceutics 13 (6) (2021)
Rémi Longuespée, Dirk Theile, Margaux Fresnais, Juergen Burhenne, Johanna Weiss, Walter Emil Haefeli
Approaching sites of action of drugs in clinical pharmacology: New analytical options and their challenges. British journal of clinical pharmacology 87 (3) (2020)
Dirk Theile, Gerd Mikus
Methadone against cancer: Lost in translation. International journal of cancer 143 (8) (2018)
Julia Schäfer, Jürgen Burhenne, Johanna Weiss, Dirk Theile
Elucidating the beneficial effects of melphalan, adriamycin, and corticoids in combination with bortezomib against multiple myeloma in vitro. Naunyn-Schmiedeberg's archives of pharmacology 392 (4) (2018)
Julia Schäfer, Johanna Weiss, Dirk Theile
Bosentan enhances in vitro bortezomib's anti-proliferative potency against multiple myeloma by mechanisms going beyond endothelin receptor blockade. British journal of haematology 184 (6) (2018)
Johanna Weiss, Jutta Kocher, Corina Mueller, Stephanie Rosenzweig, Dirk Theile
Impact of enzalutamide and its main metabolite N-desmethyl enzalutamide on pharmacokinetically important drug metabolizing enzymes and drug transporters. Biopharmaceutics & drug disposition 38 (9) (2017)

Dirk Theile.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Dirk Theile